Skip to main content

Table 1 Baseline characteristics of the study subjects in the TLGS cohort, Tehran Lipid and Glucose Study (1999–2014)

From: Application of survival tree analysis for exploration of potential interactions between predictors of incident chronic kidney disease: a 15-year follow-up study

Variables Total
n = 8238
Gender difference p-value
Men
n = 3795
Women
n = 4443
Age (years) 39.3 (13.3) 41.4 (14.2) 37.5 (12.1) 0.001
Total length of stay in the city (years) 32.9 (13.1) 34.6 (13.2) 31.5 (12.8) 0.001
BMI (kg/m2) 26.5 (4.7) 25.8 (4.1) 27.1 (5.1) 0.001
Waist circumference (cm) 87.4 (12.3) 89.1 (11.5) 86.1 (12.8) 0.001
Wrist circumference (cm) 16.7 (1.3) 17.7 (0.9) 15.9 (1.1) 0.001
Hip circumference (cm) 100.29 (9.17) 96.71 (7.23) 103.43 (9.54) 0.001
FPG (mmol/l) 4.9 (4.6–5.4) 5.1 (4.7–5.4) 4.9 (4.5–5.3) 0.001
TG (mmol/l) 1.5 (1.1–2.3) 1.7 (1.2–2.5) 1.4 (0.9–2.1) 0.001
TC (mmol/l) 5.2 (1.1) 5.1 (1.1) 5.2 (1.2) 0.07
HDL-C (mmol/l) 1.1 (0.3) 0.9 (0.2) 1.2 (0.3) 0.001
eGFR (ml/min/1.73 m2) 75.6 (10.5) 77.1 (10.8) 74.3 (10.1) 0.001
SBP (mmHg) 116.5 (17.1) 118.8 (16.7) 114.6 (17.1) 0.001
DBP (mmHg) 76.4 (10.6) 77.1(10.7) 75.8 (10.5) 0.001
Heart rate (beats/min) 79.3 (11.5) 75.3 (9.8) 82.7 (11.7) 0.001
Education
 Level 1 (illiterate) 1754 (21.3) 739 (19.5) 1015 (22.8)  
 Level 2 (< 9 years) 4831 (58.6) 2228 (58.7) 2603 (58.6) 0.001
 Level 3 (9–12 years) 1203 (14.6) 688 (18.1) 515 (11.6)  
 Level 4 (> 12 years) 450 (5.5) 140 (3.7) 310 (7.0)  
Marital status
 Single 1337 (16.2) 743 (19.6) 594 (13.4)  
 Married 6625 (80.4) 3027 (79.8) 3598 (81.0) 0.001
 Divorced/widowed 276 (3.4) 25 (0.7) 251 (5.6)  
FH-CVD in female relatives 669 (8.1) 267 (7.0) 402 (9.0) 0.001
FH-CVD in male relatives 657 (8.0) 310 (8.2) 347 (7.8) 0.568
FHD in first-degree relatives 2255 (27.4) 977 (25.7) 1278 (28.8) 0.002
PAL
 Inactivea 5458 (66.3) 2533 (66.7) 2925 (65.8) 0.802
Smoking
 Never 6207 (75.3) 2067 (54.5) 4140 (93.2)  
 Past 567 (6.9) 510 (13.4) 57 (1.3) 0.001
 Current 1339 (16.3) 1158 (30.5) 181 (4.1)  
Use of blood lipid lowering drugs 177 (2.1) 63 (1.7) 114 (2.6) 0.005
Use of blood glucose lowering drugs 234 (2.8) 100 (2.6) 134 (3.0) 0.319
Use of anti hypertensive drugs 335 (4.1) 113 (3.0) 222 (5.0) 0.001
Use of aspirin 717 (8.7) 394 (10.4) 323 (7.3) 0.001
Use of diuretics 93 (1.1) 22 (0.6) 71 (1.6) 0.001
Prevalence CVD 219 (2.7) 140 (3.7) 79 (1.8) 0.001
  1. Figures are either mean (SD) or N (%) for continuously and categorically distributed variables, respectively
  2. TLGS Tehran Lipid and Glucose Study, BMI body mass index, FPG fasting plasma glucose, TG triglyceride, TC total cholesterol, HDL-C HDL cholesterol, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, FH-CVD family history of premature cardiovascular disease, FHD family history of diabetes mellitus, PAL physical activity level, CVD cardiovascular disease
  3. aDoing exercise or labor less than three times a week or performing activities achieving < 600 metabolic equivalent of task (MET)